Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Bioequivalence study of two formulations of a sitagliptin/metformin hydrochloride extended-release tablet in healthy Chinese subjects under fasting and fed conditions: a randomized, open-label, single-dose, crossover trial

  • Lin Fang1
  • Xin Li1
  • Rongxin Ban1
  • Chenjing Wang1
  • Yi Xu1
  • Lipeng Xue2
  • Ping Shi1
  • Feifei Sun1
  • Yu Cao1
  1. 1Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University
  2. 2Clinical Research Department, Qilu Pharmaceutical (Hainan) Co., Ltd.
Read full textPDFDOICite

Abstract

Introduction: This study aimed to evaluate the bioequivalence and safety of a newly developed generic sitagliptin/metformin hydrochloride extended‐release (XR) tablet (50 mg/500 mg) compared with the reference formulation, Janumet XR, in healthy Chinese subjects under fasting and fed conditions.

Methods: This randomized, open‐label, single‐dose, two‐period, two‐sequence crossover study included 40 subjects in the fasting cohort and 36 subjects in the fed cohort. Subjects received a single dose of the test or reference formulation in each period, separated by a 5‐day washout period. Plasma concentrations of sitagliptin and metformin were determined using a validated liquid chromatography‐tandem mass spectrometry method. Bioequivalence was assessed using the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs; test/reference) of maximum plasma concentration (C max ), area under the plasma concentration‐time curve from time zero to the last quantifiable concentration (AUC 0‐t ), and area under the plasma concentration‐time curve from time zero to infinity (AUC 0‐infinity ).

Results: Under fasting conditions, the 90% CIs for the GMRs of sitagliptin for C max , AUC 0‐t , and AUC 0‐infinity were 88.24%–101.46%, 98.24%–103.15%, and 98.41%–103.33%, respectively. The corresponding values for metformin were 93.23%–103.26%, 93.00%–106.20%, and 92.89%–105.74%. Bioequivalence was also established under fed conditions for sitagliptin (C max : 88.29%–99.06%; AUC 0‐t : 96.19%–101.02%; AUC 0‐infinity : 96.07%–101.04%) and metformin (C max : 92.06% –99.39%; AUC 0‐t : 91.31%–100.06%; AUC 0‐infinity : 91.00%–99.30%). Analysis of variance showed a significant period effect for metformin AUC 0‐t and AUC 0‐infinity under fasting conditions (P < 0.05), whereas no significant formulation effect was observed (P > 0.05). Both formulations were well tolerated. Only Grade 1 or Grade 2 adverse events were reported, and no serious adverse events occurred

Discussion: The generic sitagliptin/metformin hydrochloride XR tablet was bioequivalent to the reference product under both fasting and fed conditions in healthy Chinese subjects. The generic formulation was well tolerated and may provide a safe and effective alternative for the treatment of type 2 diabetes mellitus.

Related

  1. Bioequivalence of tegomil fumarate gastro-resistant capsules versus dimethyl fumarate gastro-resistant capsules under different fed conditions: two randomized, crossover, phase I studies
    Katja Zietz, Simona Rizea Savu, Lina Remis +3
    Frontiers in neurologyPeer-reviewedCC BYFull textNeurologyEurope PMC
  2. Development of an In Vitro Permeation Test Framework For Naloxone Hydrochloride Intranasal Spray: Establishing IVIVR for Bioequivalence Assessment
    Tasmin Ara Sultana, Manar Al-Ghabeish, Steven Chopski +5
    Pharmaceutical researchPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  3. Comparative evaluation of the antipyretic and analgesic efficacy and safety of a fast-release paracetamol 650 mg formulation vs. conventional paracetamol formulations in adults with acute febrile or febrile-pain conditions: a multicenter randomized controlled trial
    Susobhan Mondal, S. K. Ashik Ikbal, Sumit Agrawal +11
    Frontiers in pain research (Lausanne, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects.
    Jianxin Wang, Kai Gu, Mingxuan Zhang +8
    Clinical pharmacology in drug developmentPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial
    Ahmed E. Altyar, Dina Y. Dessouky, Sara Abdallah Mohamed Salem +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{fang2026bioequivalence,
  title = {{Bioequivalence study of two formulations of a sitagliptin/metformin hydrochloride extended-release tablet in healthy Chinese subjects under fasting and fed conditions: a randomized, open-label, single-dose, crossover trial}},
  author = {Lin Fang and Xin Li and Rongxin Ban and Chenjing Wang and Yi Xu and Lipeng Xue and Ping Shi and Feifei Sun and Yu Cao},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1927547},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1927547/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Bioequivalence study of two formulations of a sitagliptin/metformin hydrochloride extended-release tablet in healthy Chinese subjects under fasting and fed conditions: a randomized, open-label, single-dose, crossover trial
AU  - Lin Fang
AU  - Xin Li
AU  - Rongxin Ban
AU  - Chenjing Wang
AU  - Yi Xu
AU  - Lipeng Xue
AU  - Ping Shi
AU  - Feifei Sun
AU  - Yu Cao
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1927547
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1927547/full
AB  - Introduction: This study aimed to evaluate the bioequivalence and safety of a newly developed generic sitagliptin/metformin hydrochloride extended‐release (XR) tablet (50 mg/500 mg) compared with the reference formulation, Janumet XR, in healthy Chinese subjects under fasting and fed conditions.  Methods: This randomized, open‐label, single‐dose, two‐period, two‐sequence crossover study included 40 subjects in the fasting cohort and 36 subjects in the fed cohort. Subjects received a single dose of the test or reference formulation in each period, separated by a 5‐day washout period. Plasma concentrations of sitagliptin and metformin were determined using a validated liquid chromatography‐tandem mass spectrometry method. Bioequivalence was assessed using the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs; test/reference) of maximum plasma concentration (C max ), area under the plasma concentration‐time curve from time zero to the last quantifiable concentration (AUC 0‐t ), and area under the plasma concentration‐time curve from time zero to infinity (AUC 0‐infinity ).  Results: Under fasting conditions, the 90% CIs for the GMRs of sitagliptin for C max , AUC 0‐t , and AUC 0‐infinity were 88.24%–101.46%, 98.24%–103.15%, and 98.41%–103.33%, respectively. The corresponding values for metformin were 93.23%–103.26%, 93.00%–106.20%, and 92.89%–105.74%. Bioequivalence was also established under fed conditions for sitagliptin (C max : 88.29%–99.06%; AUC 0‐t : 96.19%–101.02%; AUC 0‐infinity : 96.07%–101.04%) and metformin (C max : 92.06% –99.39%; AUC 0‐t : 91.31%–100.06%; AUC 0‐infinity : 91.00%–99.30%). Analysis of variance showed a significant period effect for metformin AUC 0‐t and AUC 0‐infinity under fasting conditions (P < 0.05), whereas no significant formulation effect was observed (P > 0.05). Both formulations were well tolerated. Only Grade 1 or Grade 2 adverse events were reported, and no serious adverse events occurred  Discussion: The generic sitagliptin/metformin hydrochloride XR tablet was bioequivalent to the reference product under both fasting and fed conditions in healthy Chinese subjects. The generic formulation was well tolerated and may provide a safe and effective alternative for the treatment of type 2 diabetes mellitus.
SN  - 1663-9812
ER  -